Solara Active Pharma Shares Price Fall After Q2FY26 Loss; Revenue Drops 10.9% YoY

Mumbai, November 6, 2025: Solara Active Pharma Sciences Ltd announced its financial results for the quarter ended Q2FY26, reporting a consolidated net loss of ₹10.10 crore. The company’s revenue also slipped by 10.9% YoY, primarily due to higher material and finance costs.

Solara Active Pharma Sciences Ltd is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs). The company is headquartered in Chennai and operates facilities across India. The company is serving major global pharmaceutical firms. It is listed on NSE and BSE trading under the tickers SOLARA and 541540, respectively.

Q2FY26 Financial Performance

The company generated ₹313.54 crore in revenue from operations during the quarter. This is a 10.9% YoY and 1.8% QoQ decrease. The company’s total income also decreased 9.6% YoY, reaching ₹314.03 crore. However, the expenses were on the rise. They totalled ₹324.13 crore for the quarter. The profit also decreased due to the increased expenses and decreased revenue. The company reported a loss of ₹10.10 crore. This is very low compared to a profit of ₹8.01 crore in the previous year. It is also very low from ₹10.52 crore in the previous quarter.

Balance Sheet & Liquidity

The company also disclosed its balance sheet as of September 30, 2025. Total assets stood at ₹2,293.43 crore, up from ₹2,231.84 crore as of March 31, 2025. Total equity also rose, reaching ₹1,257.46 crore compared to ₹1,096.91 crore. Cash and cash equivalents slightly declined to ₹3.71 crore from ₹3.95 crore on March 31, 2025.

Market Snapshot

The share price of Solara Active Pharma Sciences Limited closed at ₹566.00. This is an 8.29% or ₹51.15 decrease from its previous close of ₹617.15. The intraday range was between ₹502.30 and ₹575.00. The company has had a decent trading session. Its total market capitalisation stood at ₹2,046.84 crore. Further, it had a total traded value and volume of ₹45.50 crore and 8.14 lakh shares, respectively.

Rights Issue and Capital Update

The company has an ongoing rights issue totalling ₹449.95 crore, comprising ₹157.48 crore from application money and the remainder from calls. So far, ₹311.85 crore has been raised, including application money and ₹154.37 crore from the first call. The issue is priced at ₹375 per share, consisting of ₹10 face value and ₹365 premium. The final call of ₹134.99 crore is pending and will be made as required.

Corporate Developments

Solara Active Pharma Sciences Ltd incorporated a wholly owned subsidiary, Synthix Global Pharma Solutions Ltd, in April 2025 to explore a potential demerger of its CRAMS and Polymers businesses. Additionally, the board approved the closure of Solara Active Pharma Sciences LTDA in Brazil, effective September 16, 2025, due to its non-operational status.

REF: https://nsearchives.nseindia.com/corporate/SOLARA_06112025110125_SELetter_FinancialsSep25.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations